Brainomix, the AI-powered medtech solutions company, were selected as the winner in two categories for which it was a finalist in the Thames Valley Tech Awards 2023:  Innovative Tech Company of the Year and Life Sciences & Health Tech Company of the Year, both highly competitive categories with a number of impressive companies from the region.

Organized by The Business Magazine, the annual Thames Valley Tech Awards seeks to highlight and celebrate the strength and importance of technology in the region.  Finalists were selected across 11 categories and the winners were announced last Thursday evening at a glittering dinner held at The Select Car Leasing Stadium in Reading. Brainomix edged out ALL.SPACE, Eden Research, Oxford nanoSystems, QBox Corp and SafeToNet to win Innovative Tech Company of the Year sponsored by Blake Morgan and took the top accolade against stiff competition from IgniteData, iLoF - Intelligent Lab on Fiber, OMass Therapeutics, Oxford BioTherapeutics and RSSL in winning the Life Sciences and Health Tech Company of the Year sponsored by EY.

Judges from both categories remarked upon Brainomix’s success in recent years, particularly in the UK with a deployment of the e-Stroke platform across the majority of stroke networks in England and Wales, and the recent announcement of FDA clearance for its platform in the US market.

Accepting the awards for Brainomix, its Chief Marketing Officer, Jeff Wyrtzen said, “These awards are a true reflection of the pioneering work that our entire company contributes towards – from our world-class software developers, to our Translational Medicine team that drives our research, to our field-based team that expands our footprint and fosters broader adoption of our cutting-edge technologies. We’ve seen a tremendous trajectory over the last few years, with a number of major milestones and impressive achievements. Ultimately, though, for us it’s all about the impact that our solutions are having on patient care, improving the lives of stroke patients and fast-tracking the development of novel biomarkers that will transform Interstitial Lung Disease.”